Abstract
The current interest in the clinical use of the hematopoietic growth factors (HGF) in the treatment of patients with acute myeloid leukemia (AML) relates to the promise of reducing morbidity and improving survival through mitigating the complications of cytotoxic therapy. Another possible mode of employment of HGFs is derived from the ability of these peptides to directly stimulate leukemic cells and potentially enhance the efficacy of antileukemic therapy. Here we discuss the experimental basis and the rationale of the application of HGFs in AML and review the accumulating results from clinical studies.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Terpstra, W., Löwenberg, B. Application of myeloid growth factors in the treatment of acute myeloid leukemia. Leukemia 11, 315–327 (1997). https://doi.org/10.1038/sj.leu.2400561
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2400561
- Springer Nature Limited
Keywords
This article is cited by
-
Effectiveness and safety of granulocyte colony-stimulating factor priming regimen for acute myeloid leukemia: A systematic review and meta-analysis of the Clinical Practice Guideline for the use of G-CSF 2022 from the Japan Society of Clinical Oncology
International Journal of Clinical Oncology (2024)
-
A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial
BMC Cancer (2008)
-
A study on the antitumoral and differentiation effects of peganum harmala derivatives in combination with atra on leukaemic cells
Archives of Pharmacal Research (2007)
-
Long-term survival data from a phase 3 study of Filgrastim as an adjunct to chemotherapy in adults with de novo acute myeloid leukemia
Leukemia (2006)